新产业前沿关注者
您现在的位置：&&>&&>&&>&正文
斯坦福大学反向DNA疫苗开创一型糖尿病新疗法
日讯 /BIOON/ -- 斯坦福大学教授Lawrence Steinman领导的团队向公众宣布其研制的治疗一型的疫苗取得突破性进展。这种名为TOL-3021的疫苗是一种以基因工程技术制作的反向，这种疫苗可以靶向抑制异常表达的T细胞以保护胰岛B细胞不受伤害，从而达到治疗一型的目的。（生物谷）
详细英文报道：
A brand new biotech created by a team of professors from Stanford University burst into public view today, drawing headlines around the world for a new therapeutic approach to Type 1 diabetes that aims to completely change the standard of care in the field.
Stanford Professor Lawrence Steinman spearheaded the creation of Tolerion and yesterday reported that the company had achieved key proof-of-concept data for a new "reverse" DNA vaccine--TOL-3021, described as an engineered DNA plasmid that expresses proinsulin--that is designed to rein in the errant T-cell attack that triggers juvenile diabetes by protecting the pancreatic beta cells needed to keep the patient healthy.
Over the course of a Phase II study 80 patients received one of four doses over 12 weeks. The investigators tracked an improvement in C-peptide--a prime biomarker for pancreatic beta cell functioning and insulin production.
"For example, at week 15, C-peptide increased by 19.5% from baseline with the 1 mg dose of TOL-3021, compared to a decrease of 8.8% in patients on placebo (p&0.026)," says the company's release. "Furthermore, an indicator of underlying disease activity, the number of CD8 T-cells reactive to proinsulin, declined with TOL-3021 treatment, while T-cells against other antigens, such as infectious pathogens, were unaffected (p&0.006)."
Investigators have been trying for years now to create synthetically engineered DNA vaccines that can produce an immune response against targets like HIV. But Tolerion is using the technology to suppress the immune system, specifically targeting those T-cells that attack the pancreas.
The news was picked up by all the major financial news wires, with patient groups adding their applause.
"For the first time we have evidence that this particular type of vaccine has an effect in preserving insulin production in humans," said Karen Addington, the U.K. chief executive of the Type 1 diabetes charity JDRF. "This is a significant step forward on the journey towards a world without Type 1 diabetes. We will build on this exciting DNA vaccine approach. Research into Type 1 vaccines is a priority for JDRF's multimillion-pound global research program. But it is early days. Clinical use is still some time away."
Up until now the only treatment for Type 1 diabetes was insulin replacement, a 100-year old therapy that often disrupts patients' lives with a host of side effects, Steinman tells FierceBiotech today. On the other hand, it's also well understood by doctors and patients, who can live normal lives with the proper care. The challenge here is to develop a new treatment that is safe for patients with a targeted immunosuppressant that controls diabetes but won't disable the immune system, exposing patients to serious diseases.
Tolerion was set up only two months ago, he adds, but its history dates back 10 years. Bayhill Therapeutics originally had the platform technology and a $350 million deal with Genentech. But an attempt to go public in 2008 was derailed by the financial crisis, says Steinman, and Genentech decided to drop their involvement after Roche acquired the company. Bayhill was wound down and now Tolerion has the platform technology--which Steinman says can be used to develop other therapies for diseases like hyperthyroidism and hemophilia A. And the four founders from Stanford are scouting for venture backing as well as a major league partner to take this forward.
Type 1 diabetes has proven to be a very tough target in the biopharma world. Tolerx partnered with GlaxoSmithKline ($GSK) on their antibody, otelixizumab, which failed decisively in a Phase III study that read out in the spring of 2011. Like Tolerion, Tolerx had tried to protect pancreatic beta cells, looking for a significant improvement in C-peptide by targeting the CD3 receptor on T cells. But months after the late-stage failure the company was wrapped up, wiping out a $150 million in investment cash. Another anti-CD3 antibody at MacroGenics--partnered with Eli Lilly ($LLY)--failed a Phase III study in late 2010.
Diabetes is also a very expensive disease field to work in, which is why the anti-CD3 companies both had big pharma partners to fund late-stage work. Tolerion will now see if its rebirth coinciding with promising Phase II data can spur a few of the big players in this disease space to take a closer look.
&关键词：斯坦福大学,反向DNA疫苗,一型糖尿病
信息来源:生物谷
没有相关生物制药
关注生物制药、创投、项目技术的新鲜资讯。需更多信息，也请加入列表。医生回答专区（1条回答）
免费电话咨询：
病情分析：
对答案不太满意？
你好。需要积极服药控制的，建议口服二甲双胍和吡格列酮，平时注意控制饮食，低糖低脂肪饮食，尽量减少面食的摄入，多食用蔬菜，加强体育锻炼，保持良好的心态，定期监测
(求医提醒:因不能面诊患者，无法全面了解病情，以上建议仅供参考，具体诊疗请一定到正规医院在医生指导下进行。)
本回答来自：
山东冠县甘官屯乡卫生院
无需注册，立即提问，正规三甲医院专家为您解答，100%回复！
免费 向糖尿病医生咨询
最少 5 个字
参考价格:￥4.5-57.6
主治：1本品作为首选或选用药物应用于下列疾病：（1）立克次体病，包括流行性斑疹伤寒、地方性斑...
参考价格:￥9-19.7
主治：益气养阴，活血化瘀，通经活络。主治气血两虚糖尿病，调整糖，脂肪，蛋白质，代谢紊乱及糖尿...
参考价格:￥3.3-10
主治：1.异烟肼与其它抗结核药联合，适用于各型结核病的治疗，包括结核性脑膜炎以及其他分枝杆菌...
参考价格:￥3.3-10
主治：1.异烟肼与其它抗结核药联合，适用于各型结核病的治疗，包括结核性脑膜炎以及其他分枝杆菌...
无需注册，立即提问，正规三甲医院专家为您解答，100%回复！
糖尿病医生后使用快捷导航没有帐号？
扫一扫，访问微社区
查看: 2048|回复: 5
张泽全《糖尿病治疗新概念》骗子而已
注册:,精华:,
骗子的头衔：
张泽全，美籍华人，出生于山西定襄中医世家，现任中华中医药学会糖尿病分会副主任、美国国际糖尿病研究中心主任
这头衔好假。
就连美国前总统布什每年都会给他寄来贺卡，其中2004年的贺卡中写道：“祝贺你在治疗糖尿病领域中的突破进展，感谢您为世界人民健康做出的巨大贡献。”
布什给他寄贺卡，太搞了。
张泽全所发明的这种中药秘方：1997年获得首届国际爱因斯坦新发明国际金奖；1998年获得美国FDA批准证书，进入美国市场；2004年获得国家发明专利，专利号ZL。
FDA 会给中药批准证书，那基本没有。
注册:,精华:,
在”兰州晨报“上做的虚假广告
一种治疗糖尿病的专利中药秘方已问世！( 2:34:29)
02:34:29　来源: 兰州晨报(兰州)　
糖尿病，世界卫生组织都认为是终身病，而他认为98%的糖尿病不是终身病，只有2%的Ⅰ型先天型胰岛功能丧失和缺乏的才是终身病，他的这一观点经北京电视台、中央电视台、凤凰卫视等多家媒体爆出就引起了世界轰动，他是谁？
张泽全，美籍华人，出生于山西定襄中医世家，现任中华中医药学会糖尿病分会副主任、美国国际糖尿病研究中心主任，早在1997年就提出糖尿病不是终身病，他的这一观点已经有许多国家相关部门和权威人认可，并予以题词肯定，经众多三甲医院临床显示疗效确切，经他治好的糖尿病患者也数以万计。
张俊卿，太原小店北格镇南格村人，今年57岁，2002年发现糖尿病，感觉身上没劲，吃饭多，晚上小便也多，血糖16点（空腹），吃了张泽全专利中药一个多月，无力和不适感全没了，用药半年，血糖、尿糖都正常了，现在每年吃两个月专利中药，其它药物全不吃，血糖基本上一个星期测一次，保持在6以下，身体各方面都正常。这种患者在张泽全手中数不胜数，包括国内外的名流政要。
韩国前副总统前民主党总裁，患糖尿病多年，在服用张泽全中药后，糖尿病眼病等多种并发症全部恢复，并且血糖恢复正常，康复后高兴地写下了“中华一绝，妙手回春”赠送张泽全，就连美国前总统布什每年都会给他寄来贺卡，其中2004年的贺卡中写道：“祝贺你在治疗糖尿病领域中的突破进展，感谢您为世界人民健康做出的巨大贡献。”
张泽全所发明的这种中药秘方：1997年获得首届国际爱因斯坦新发明国际金奖；1998年获得美国FDA批准证书，进入美国市场；2004年获得国家发明专利，专利号ZL。
为了让更多的糖尿病患者早日受益，拨打400-857-2608电话，就可免费领取张泽全发明的治疗糖尿病的专利产品一盒，并赠送一本《糖尿病治疗新概念》（华人医学优秀作品），送完即止，活动仅限20名。
netease 本文来源：每日甘肃网-兰州晨报
注册:,精华:,
中医中药是包治百病的，我们这儿的小中医都拍胸保证的，他治不了1型，已经够差劲了。
注册:,精华:,
注册:,精华:,
这次诺贝尔奖他没有拿，太搞笑了。
注册:,精华:,
张泽全变美籍华人了？可耻！
看看这个吧：
Powered by